Schedule 13G/A

INDV Schedule 13G/A filing by BlackRock

BlackRock reported beneficial ownership of 17.8M shares, representing 14.3% of Indivior Pharmaceuticals, Inc. in this filing.

FiledJan 8, 2026

Ownership dateDec 31, 2025

Reported shares17.8M

Reported ownership14.3%

Ownership details

Voting and dispositive power reported in the filing

These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.

Sole voting power 17.6M

Shared voting power 17.8M

Sole dispositive power 17.8M

Shared dispositive power 17.8M

Price context

Price dates alongside the ownership filing

Price data provides market context around the disclosure. It does not identify the filer’s actual transaction price.

Close near filing date$35.51as of Jan 8, 2026

Latest tracked price$38.73as of Aug 5, 2026

Source

Original filing and accession

Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.

Reporting filer: BlackRock
CIK: CIK0002012383
Accession: 0002012383-26-000035
Form: Schedule 13G/A

Open SEC filing View INDV ownership history

Read the filing in context

Understand what a Schedule 13 filing does—and does not—tell you.

How to read a Schedule 13G → Does a 13G mean the shares were just bought? → Filing date vs. ownership date →